MedTrace Logo

Daily Doxycycline to Inform Sexually Transmitted Infection Prophylaxis Regimens

NCT06545656 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2026-05-01

Study results available
· View outcomes & findings →

Summary

The goal of this project is to collect data regarding the concentrations of doxycycline in mucosal tissues after daily dosing for 7 days in people assigned male sex at birth (AMAB) and assigned female sex at birth (AFAB) to inform future studies of doxycycline to protect against bacterial sexually transmitted infections (STIs).

Conditions

  • Sexually Transmitted Infection

Interventions

DRUG

Doxycycline

Doxycycline (DOX) will be given orally at 100mg doses. Participants will take the study medication for 7 consecutive days.

Sponsors & Collaborators

Principal Investigators

  • Colleen Kelley, MD, MPH · Emory University

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
59 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-09-13
Primary Completion
2025-04-29
Completion
2025-04-29
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06545656 on ClinicalTrials.gov